In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elan, Beyond Genomics ally in Alzheimer's drug discovery

Executive Summary

In its first corporate partnership, Beyond Genomics (systems biology technology) will apply its chemometric and biometric tools in a two-year joint venture with Elan to identify biomarkers and drug targets to diagnose and treat Alzheimer's disease. Elan made a $5mm up-front equity investment in the company.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies